Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares were down 7.6% on Monday . The stock traded as low as $20.10 and last traded at $20.18. Approximately 533,806 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 1,346,057 shares. The stock had previously closed at $21.83.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on IMNM shares. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Immunome in a report on Wednesday, May 13th. Barclays started coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Truist Financial increased their price objective on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Finally, Wall Street Zen lowered shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.17.
Get Our Latest Analysis on Immunome
Immunome Stock Performance
Immunome (NASDAQ:IMNM – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. On average, analysts forecast that Immunome, Inc. will post -2.26 earnings per share for the current year.
Insider Activity
In related news, insider Jack Higgins sold 9,438 shares of the stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $21.64, for a total value of $204,238.32. Following the sale, the insider directly owned 22,000 shares in the company, valued at $476,080. This trade represents a 30.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Philip Wagenheim sold 28,200 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $20.65, for a total transaction of $582,330.00. Following the completion of the sale, the director owned 341,147 shares in the company, valued at $7,044,685.55. This represents a 7.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 139,438 shares of company stock valued at $2,964,664. Insiders own 7.21% of the company’s stock.
Institutional Trading of Immunome
A number of hedge funds have recently modified their holdings of IMNM. Assetmark Inc. acquired a new stake in shares of Immunome in the 3rd quarter valued at approximately $39,000. KBC Group NV acquired a new stake in shares of Immunome in the 1st quarter valued at approximately $60,000. BNP Paribas Financial Markets raised its position in shares of Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares during the period. Strs Ohio acquired a new stake in shares of Immunome in the 4th quarter valued at approximately $64,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after acquiring an additional 3,802 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.
Immunome Company Profile
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
Featured Articles
- Five stocks we like better than Immunome
- Tomato Prices Are Spiking, and These 2 Food Stocks Could Feel the Squeeze
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
